In vitro activity of oral antibiotics against extensively drug-resistant Shigella isolates: a pharmacokinetic/pharmacodynamic perspective on the intracellular pathogenesis paradigm
Journal of Medical Microbiology · 13.11.2026 · 75 (11)
DOI: 10.1099/jmm.0.002213 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Microbiology, erschienen am 13.11.2026. Verfasst von Dhanalakshmi Solamalai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Microbiology, Christian Medical College, Vellore, India. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Shigella, Dysentery, Bacillary, Drug Resistance, Multiple, Bacterial. Die Arbeit nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Introduction
Shigellosis is emerging as a critical therapeutic challenge in low- and middle-income countries (LMICs) due to the emergence of extensively drug-resistant (XDR) strains resistant to azithromycin, third-generation cephalosporins and fluoroquinolones. The obligate intracellular lifestyle of Shigella , characterized by epithelial cell invasion and actin-mediated intracellular spread, limits the predictive value of conventional extracellular susceptibility testing alone. Hypothesis/Gap Statement. The loss of effective oral antibiotics for XDR Shigella represents a major unmet clinical and public health need, particularly in endemic LMIC settings where outpatient management is essential. Current breakpoint-based susceptibility interpretations primarily reflect extracellular antimicrobial exposure and may inadequately capture the intracellular pharmacodynamic requirements of Shigella infection. Furthermore, integrated evaluation of in vitro susceptibility together with pharmacokinetic–pharmacodynamic (PK/PD) and intracellular exposure parameters for candidate oral agents against XDR Shigella remains limited.
Aim
To evaluate the molecular resistance profiles, in vitro activity and PK/PD applicability of candidate oral antibiotics against XDR Shigella isolates. Methodology. Between 2010 and March 2025, 1,823 non-duplicate clinical Shigella isolates were screened at a tertiary care centre in South India. Fifty-two isolates fulfilled XDR criteria: azithromycin MIC ≥32 mg l −1 , ceftriaxone MIC >4 mg l −1 and ciprofloxacin MIC >1 mg l −1 . PCR assays targeted blaCTX-M , blaDHA , blaCMY , blaVIM , blaNDM , mphA , msrE , ermB , qnrS and qnrB . MICs for amoxicillin–clavulanate, cefpodoxime–clavulanate, fosfomycin, mecillinam and faropenem were determined using broth or agar dilution methods and interpreted using Clinical and Laboratory Standards Institute (CLSI) M100 (2025) or literature-derived PK/PD thresholds. Results. β -Lactamase genes and mphA were detected in 96.2% of isolates, whilst qnrS / qnrB occurred in 53.8%. Cefpodoxime–clavulanate and faropenem showed 100% susceptibility, followed by fosfomycin (98.1%) and mecillinam (94.2%). MIC50/MIC90 (mg l −1 ) were 0.5/0.5 for faropenem, 0.25/2 for mecillinam and 0.25/2 for cefpodoxime–clavulanate. However, PK/PD analysis suggested that several agents lacked sustained intracellular exposure despite favourable MICs.
Conclusion
Favourable in vitro susceptibility did not consistently translate into predicted intracellular therapeutic adequacy. These findings support PK/PD-informed assessment beyond MIC-based interpretation for managing XDR shigellosis and highlight the urgent need for effective oral therapeutic options for XDR Shigella infections
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Microbiology, Christian Medical College, Vellore, India.
- Department of Clinical Microbiology and Infectious Diseases, Chacha Nehru Bal Chikitsalaya, Delhi, India.
- Department of Microbiology, Mahatma Gandhi University of Medical Sciences & Technology, Jaipur, India.
- Department of Microbiology, Rainbow Children's Hospital, Chennai, India.
- Descriptive Research Division, Indian Council of Medical Research, New Delhi, India.
Förderung
- Indian Council of Medical Research
Zitieren
APA
Solamalai, D., Irulappan, M., Bakthavatchalam, Y. D., Selvam, K., Qureshi, S., Sabharwal, E. R., S, N., Abirami, B., G, V., P, S., Rayala, R., Walia, K., & Veeraraghavan, B. (2026). In vitro activity of oral antibiotics against extensively drug-resistant Shigella isolates: a pharmacokinetic/pharmacodynamic perspective on the intracellular pathogenesis paradigm. Journal of Medical Microbiology, 75(11). https://doi.org/10.1099/jmm.0.002213
Vancouver
Solamalai D, Irulappan M, Bakthavatchalam YD, Selvam K, Qureshi S, Sabharwal ER, et al. In vitro activity of oral antibiotics against extensively drug-resistant Shigella isolates: a pharmacokinetic/pharmacodynamic perspective on the intracellular pathogenesis paradigm. Journal of Medical Microbiology. 2026;75(11). doi:10.1099/jmm.0.002213
BibTeX
@article{Solamalai2026,
author = {Solamalai, Dhanalakshmi and Irulappan, Madhumathi and Bakthavatchalam, Yamuna Devi and Selvam, Karnan and Qureshi, Shariqa and Sabharwal, Ekadashi Rajni and S, Nivedana and Abirami, Baby and G, Venkatalakshmipriya and P, Sridhar and Rayala, Ramprakash and Walia, Kamini and Veeraraghavan, Balaji},
title = {In vitro activity of oral antibiotics against extensively drug-resistant Shigella isolates: a pharmacokinetic/pharmacodynamic perspective on the intracellular pathogenesis paradigm},
journal = {Journal of Medical Microbiology},
year = {2026},
volume = {75},
number = {11},
doi = {10.1099/jmm.0.002213}
}
EUVIMED